Drug intelligence / Profile preview

CR influenza virus vaccine

Development stage: Preclinical
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

The CR influenza virus vaccine is a live attenuated, cold recombinant vaccine designed to prevent influenza. It is administered intranasally and has been studied for its effects on pulmonary function in both healthy and asthmatic adults. As a live attenuated vaccine, it contains a weakened form of the influenza virus, which aims to induce an immune response without causing severe illness. The 'cold recombinant' aspect likely refers to genetic modifications that allow the virus to replicate effectively in the cooler temperatures of the upper respiratory tract, making it suitable for intranasal delivery.

Beyond the preview

Go deeper on CR influenza virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR influenza virus vaccine.

Explore the full profile